Dataset from A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant
atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant
therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy
consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit
with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period,
which consisted of standardized blood sample collection and Chest CT Scans, for up to 2
years. All participants were monitored for disease recurrence and survival for up to 3 years
after last dose of study drug.